share_log

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K: Current report

Allarity Therapeutics | 8-K：重大事件
美股SEC公告 ·  10/11 08:03

Moomoo AI 已提取核心信息

Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.
Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has successfully regained compliance with the Nasdaq's minimum bid price requirement, as confirmed by a formal notice from The Nasdaq Stock Market, LLC on October 9, 2024. The company's common stock had previously failed to maintain the required $1.00 minimum closing bid price over a 30-day period, but has since achieved compliance by maintaining a closing bid price of $1.00 or more for 20 consecutive trading days starting September 11, 2024. Following this achievement, Allarity issued a press release on October 10, 2024, to announce its regained compliance. The company's CEO, Thomas Jensen, expressed satisfaction with the resolution of the compliance issue and emphasized the company's continued focus on advancing its stenoparib program, particularly the Phase 2 trial for advanced ovarian cancer. Stenoparib is a dual-targeted inhibitor of PARP1/2 and Tankyrase 1 and 2, with potential therapeutic benefits in cancer treatment due to its unique action on the Wnt signaling pathway. Allarity holds exclusive global rights for the development and commercialization of stenoparib.
Allarity Therapeutics股份有限公司，一家临床阶段的生物制药公司，已成功恢复符合纳斯达克的最低买盘要求，由纳斯达克证实，2024年10月9日纳斯达克证券市场有限公司正式通知。该公司的普通股此前未能保持所需的每股最低$1.00的收盘买盘价格超过30天，但自2024年9月11日开始，连续20个交易日保持收盘买盘价格为$1.00或以上后，已达到合规标准。在取得这一成就后，Allarity于2024年10月10日发布新闻稿宣布已重新符合合规要求。该公司的首席执行官Thomas Jensen对合规问题的解决表示满意，并强调公司将继续专注于推进其stenoparib项目，尤其是针对爱文思控股卵巢癌的2期试验。Stenoparib是PARP1/2和Tankyrase 1和2的双靶点抑制剂，由于其在Wnt信号通路上的独特作用，具有癌症治疗的潜在治疗益处。Allarity拥有stenoparib的独家全球开发和商业化权。
Allarity Therapeutics股份有限公司，一家临床阶段的生物制药公司，已成功恢复符合纳斯达克的最低买盘要求，由纳斯达克证实，2024年10月9日纳斯达克证券市场有限公司正式通知。该公司的普通股此前未能保持所需的每股最低$1.00的收盘买盘价格超过30天，但自2024年9月11日开始，连续20个交易日保持收盘买盘价格为$1.00或以上后，已达到合规标准。在取得这一成就后，Allarity于2024年10月10日发布新闻稿宣布已重新符合合规要求。该公司的首席执行官Thomas Jensen对合规问题的解决表示满意，并强调公司将继续专注于推进其stenoparib项目，尤其是针对爱文思控股卵巢癌的2期试验。Stenoparib是PARP1/2和Tankyrase 1和2的双靶点抑制剂，由于其在Wnt信号通路上的独特作用，具有癌症治疗的潜在治疗益处。Allarity拥有stenoparib的独家全球开发和商业化权。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间